Bellerophon Therapeutics adds Ted Wang to its Board of Directors

– USA, NJ – Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Ted Wang, Ph.D., Chief Investment Officer of Puissance Capital Management, to its Board of Directors. Bellerophon’s Board now includes 10 members.

Dr. Wang is the Chief Investment Officer of Puissance Capital Management, a global asset manager founded in 2015 with offices in the U.S. and China. Puissance was the lead investor in Bellerophon’s recently completed $23.4 million private placement. Prior to founding Puissance, Dr. Wang was a Partner of Goldman Sachs & Co. in New York. During his 18-year tenure at Goldman Sachs, he held many leadership positions, most recently as Co-Head of U.S. Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. Dr. Wang holds a Ph.D. in Physics from the University of Minnesota, an M.B.A. from the University of Texas, Austin, and a B.S. from Fudan University, China.

“We are very pleased to welcome Ted to our Board,” said Jonathan Peacock, Chairman of the Board of Directors of Bellerophon Therapeutics. “He shares our excitement for the potential of the INOpulse platform and has already built a great relationship with the Company. We know that Ted will bring great value in working with the Board to help guide the future development of Bellerophon.”

“I am pleased to be joining Bellerophon’s Board at such an exciting time in the Company’s development,” said Dr. Wang. “With a strong balance sheet and rapidly developing programs in PAH, and Pulmonary Hypertension associated with Interstial Lung Disease and COPD, Bellerophon is well-positioned for future success. I look forward to working with the Board and supporting the Company’s continued development.”

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>